2qj4: Difference between revisions

Revision as of 19:56, 28 July 2008

This article has been automatically seeded. Changes to this page should pertain to the PDB entry only and not to the protein or biomolecule in general.

File:2qj4.png

Template:STRUCTURE 2qj4

A Mechanistic Basis for Converting a Receptor Tyrosine Kinase Agonist to an AntagonistA Mechanistic Basis for Converting a Receptor Tyrosine Kinase Agonist to an Antagonist

Template:ABSTRACT PUBMED 17804794

About this StructureAbout this Structure

2QJ4 is a Single protein structure of sequence from Mus musculus. Full crystallographic information is available from OCA.

ReferenceReference

A mechanistic basis for converting a receptor tyrosine kinase agonist to an antagonist., Tolbert WD, Daugherty J, Gao C, Xie Q, Miranti C, Gherardi E, Woude GV, Xu HE, Proc Natl Acad Sci U S A. 2007 Sep 11;104(37):14592-7. Epub 2007 Sep 5. PMID:17804794

Page seeded by OCA on Mon Jul 28 19:56:44 2008

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA

@@ Line 1: / Line 1: @@
-[[Image:2qj4.gif|left|200px]]
+{{Seed}}
+[[Image:2qj4.png|left|200px]]
 <!--
@@ Line 9: / Line 10: @@
 {{STRUCTURE_2qj4|  PDB=2qj4  |  SCENE=  }}
-'''A Mechanistic Basis for Converting a Receptor Tyrosine Kinase Agonist to an Antagonist'''
+===A Mechanistic Basis for Converting a Receptor Tyrosine Kinase Agonist to an Antagonist===
-==Overview==
+<!--
-Hepatocyte growth factor (HGF) activates the Met receptor tyrosine kinase by binding and promoting receptor dimerization. Here we describe a mechanistic basis for designing Met antagonists based on NK1, a natural variant of HGF containing the N-terminal and the first kringle domain. Through detailed biochemical and structural analyses, we demonstrate that both mouse and human NK1 induce Met dimerization via a conserved NK1 dimer interface. Mutations designed to alter the NK1 dimer interface abolish its ability to promote Met dimerization but retain full Met-binding activity. Importantly, these NK1 mutants act as Met antagonists by inhibiting HGF-mediated cell scattering, proliferation, branching, and invasion. The ability to separate the Met-binding activity of NK1 from its Met dimerization activity thus provides a rational basis for designing Met antagonists. This strategy of antagonist design may be applicable for other growth factor receptors by selectively abolishing the receptor activation ability but not the receptor binding of the growth factors.
+The line below this paragraph, {{ABSTRACT_PUBMED_17804794}}, adds the Publication Abstract to the page
+(as it appears on PubMed at http://www.pubmed.gov), where 17804794 is the PubMed ID number.
+-->
+{{ABSTRACT_PUBMED_17804794}}
 ==About this Structure==
@@ Line 32: / Line 36: @@
 [[Category: Hgf/sf]]
 [[Category: Hormone/growth factor]]
-''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May  4 15:02:40 2008''
+''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jul 28 19:56:44 2008''